Conferences

Viewing 1-20 of 12177 articles

SES AUA 2025: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel Accounting for Subsequent Therapy: A Sensitivity Analysis from ARASENS

SES AUA 2025: Early Longitudinal Outcomes of Black Men Undergoing PSA Screening Following Implementation of a PSA-Based Risk Stratification Algorithm in a Health System-Wide Initiative

SES AUA 2025: Outcomes of Men with High-Risk Biochemically Recurrent Prostate Cancer who Suspended Enzalutamide Monotherapy Treatment in the Phase 3 EMBARK Study

SES AUA 2025: Phase 1 Trial of Mevrometostat (PF-06821497), a Potent and Selective Inhibitor of EZH2, in CRPC

SES AUA 2025: Validation of PAM50 for Predicting Progression in Active Surveillance: Results from the Miami MAST Prospective Clinical Trial

SES AUA 2025: PSA Dynamics from the Phase 3 EMBARK Trial: A Post Hoc Analysis

SES AUA 2025: American Urological Association Annual Census Identifies 39% of Practicing Urologists Utilize Unhealthy Coping Mechanisms for Burnout and Stress

SES AUA 2025: Incidence of New Mental Health Diagnoses in Testicular Cancer Survivors

SES AUA 2025: Efficacy and Safety of Darolutamide plus Androgen Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase 3 ARANOTE Trial

SES AUA 2025: Germline Testing for Renal Cancers – How Age and Tumor Characteristics Affect Pathogenic Variants

SES AUA 2025: Identifying Key Mutations Linked to Metastasis in Clear Cell Renal Cell Carcinoma: A GENIE Database Analysis

SES AUA 2025: Evaluation of Systemic Therapy and Surgical Consolidation in Patients with Node Positive UTUC

SES AUA 2025: Association of Somatic Gene Mutations in Urothelial Cancer Based on Location in the Bladder

SES AUA 2025: Development and Initial Experience of a Dedicated Female Bladder Cancer Clinical Care Coordinator Role

SES AUA 2025: Multicenter Experience with First-Line Intravesical Gemcitabine + Docetaxel versus BCG for high risk NMIBC

SES AUA 2025: Systemic Therapy for Renal Cell Carcinoma with a Tumor Thrombus: Management and Outcomes from the Intercontinental Collaboration on Renal Cell Carcinoma Database

SES AUA 2025: ENVISION: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single-Arm, Open-Label, Phase 3 Trial

SES AUA 2025: LEGEND: Phase 1/2 Study of Detalimogene Voraplasmid, a Novel, Investigational, Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS

SES AUA 2025: Oncologic Efficacy of Reduced versus Standard-Dose BCG for NMIBC

SES AUA 2025: Assessing Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from The MAST Trial

1
2
3
4
5
6
7
8
9
10